Fmr LLC Sells 95,723 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Fmr LLC trimmed its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 28.0% in the 3rd quarter, Holdings Channel reports. The fund owned 246,106 shares of the company’s stock after selling 95,723 shares during the quarter. Fmr LLC’s holdings in Neurocrine Biosciences were worth $28,356,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of the business. Ashton Thomas Private Wealth LLC bought a new position in Neurocrine Biosciences in the second quarter worth $28,000. Innealta Capital LLC bought a new position in Neurocrine Biosciences in the second quarter worth $30,000. EdgeRock Capital LLC bought a new position in Neurocrine Biosciences in the second quarter worth $35,000. Blue Trust Inc. lifted its position in Neurocrine Biosciences by 171.9% in the third quarter. Blue Trust Inc. now owns 348 shares of the company’s stock worth $40,000 after purchasing an additional 220 shares during the period. Finally, Plato Investment Management Ltd lifted its position in Neurocrine Biosciences by 44.1% in the second quarter. Plato Investment Management Ltd now owns 425 shares of the company’s stock worth $59,000 after purchasing an additional 130 shares during the period. 92.59% of the stock is owned by institutional investors.

Neurocrine Biosciences Stock Up 0.8 %

Shares of NBIX stock opened at $129.12 on Tuesday. The stock has a 50-day moving average price of $120.61 and a 200 day moving average price of $130.90. The firm has a market cap of $13.07 billion, a price-to-earnings ratio of 34.62 and a beta of 0.34. Neurocrine Biosciences, Inc. has a 12 month low of $110.95 and a 12 month high of $157.98.

Insider Buying and Selling

In other Neurocrine Biosciences news, insider Jude Onyia sold 2,331 shares of the firm’s stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $126.29, for a total transaction of $294,381.99. Following the transaction, the insider now owns 15,449 shares in the company, valued at approximately $1,951,054.21. This trade represents a 13.11 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 4.30% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. Barclays cut their price objective on Neurocrine Biosciences from $180.00 to $160.00 and set an “overweight” rating for the company in a report on Monday, September 9th. Royal Bank of Canada cut their price objective on Neurocrine Biosciences from $136.00 to $133.00 and set a “sector perform” rating for the company in a report on Friday, October 4th. HC Wainwright reissued a “buy” rating and set a $190.00 price objective on shares of Neurocrine Biosciences in a report on Friday, November 1st. BMO Capital Markets cut their price objective on Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating for the company in a report on Thursday, October 17th. Finally, Jefferies Financial Group lifted their price objective on Neurocrine Biosciences from $177.00 to $189.00 and gave the company a “buy” rating in a report on Monday, August 19th. Five research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $163.91.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.